MedTrace Logo

Drug-Drug Interaction Study: ASP2151 and Midazolam

NCT02403635 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2019-02-21

Study results available
· View outcomes & findings →

Summary

CYP3A4 is involved in the metabolism of many drugs. So, it is important to assess in vivo the induction effect of ASP2151 on that enzyme to determine the extent of any possible drug interactions. The aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP3A4 probe substrate midazolam.

Conditions

  • Healthy

Interventions

DRUG

Midazolam

DRUG

ASP2151

Sponsors & Collaborators

  • Maruho Europe Limited

    lead INDUSTRY

Principal Investigators

  • Joachim Dr Kempeni · Maruho Europe Ltd

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02403635 on ClinicalTrials.gov